NYSE:BSX

Boston Scientific Corp (BSX)

51.19
+0.73 (1.45%)
as of Aug 11, 2026, 8:00:00 pm Market Open.
101 watching
0
Investor Insights
star iconAug 11, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Boston Scientific Corp (BSX-N) has experienced significant challenges over the past year, with major concerns regarding its organic growth and market position. Experts pointed out that the company has seen a breakdown in its uptrend and is now dealing with lower highs and lows, which has negatively impacted its stock price. Many analysts note that while the company is a leader in the medical device sector, it faces tough competition from peers such as Medtronic, Abbott, and Johnson & Johnson. The recent adjustments in growth projection have raised red flags regarding its valuation, with some analysts advising caution. Despite its strong fundamentals and long-term growth potential in the aging demographics market, the near-term technical outlook remains weak, and the consensus leans towards a watchful approach.

consensus icon
Consensus
Negative
valuation icon
Valuation
Overvalued
review icon
Similar
MDT
PAST TOP PICK

(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.

BUY
Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.
BUY
They've done a good job turning around in the past 7 years with a new CEO. Margins will continue to rise with high single-digit growth. Legal settlements and tax issues are behind them, thus freeing up their cash. This is a big holding for him.
HOLD
Likes 2-year time horizon. A stellar performer. Executing on top and bottom line. An example of how margins should be. Couple of new products are coming out, and one of best organic growth profiles in the sector. This quarter was the first hiccup in a long time, but the market gave them a pass. He'll give them another quarter to prove themselves.
BUY
BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it.
BUY
He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions.
BUY

He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model.

TOP PICK

The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78)

BUY

He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates.

BUY

On the 5 year chart you can see it is in an uptrend. It is quite tradable. It began to find a lid just under $30. Buy in the low $20s and sell in the high $20’s. Don’t own it for the long run.

HOLD

No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

COMMENT

If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here.

HOLD

An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.

BUY

Thinks this is a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.

DON'T BUY
In the last 9 months they had their heart defibrillator withdrawn from the US market because of FDA problems. Would steer clear of this one.